GammaRips

KOD

BULL
2026-09-29

Overnight Scan Record · Healthcare

See the 2026-09-29 Morning Briefing

This is one row from the GammaRips nightly scan of about 3,500 optionable US stocks, tracked to its outcome. What membership means depends on the scan date. For scan dates from 2026-08-24, it is a liquidity rank: the 100 most liquid names, bullish only. For earlier scan dates, the scan selected on unusual options activity and included bearish names. The two sets are not one population. Data, not a recommendation. New here? See how the pool is built → Or put your AI agent on this data →

Score
6/10

Descriptive context. Not a quality rank and not a forecast.

Move
172.6%
Flow
$35.6M
Engine Flags(1 of 5 patterns matched. Descriptive, not a trade signal.)
Move Above 2x ATRThe session move was more than 2x the average true range.
AI Analysis

Model-written context on what the scan saw that night. It is context, not advice and not a trade instruction.

KOD BULLISH options flow reflects institutional positioning in the wake of the highly successful Phase 3 DAYBREAK topline results, where the massive $32.7 million premium concentrated in call options as the stock rallied past multi-year resistance levels. This volume expansion signals structural institutional Accumulation as the market reprices the commercial probability of Zenkuda and KSI-501 following their successful non-inferiority trials against Eylea. Risk factor: Extreme post-binary implied volatility crush could decay premium rapidly if the stock enters a short-term consolidation phase ahead of the October AAO presentation.
Flow Breakdown
Call Volume
$32.8M
Put Volume
$2.9M
Flow Intent
DIRECTIONAL
Catalyst
Regulatory
More Bullish Flow · 2026-09-29
Engine-Selected Contract
The contract the engine priced for this row. Descriptive, not a recommendation.
Contract—
Strike—
Expiration—
Delta—
Key Levels
Resistance$95.77
Support$34.21
Price$89.92
SMA 50 / 200$39 / $34
52W Range$6 — $96
RSI (14)90
News & Catalyst Analysis

Key Headline

Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration

News Summary

Kodiak Sciences surged over 170% following the announcement of highly positive, pivotal Phase 3 DAYBREAK topline results for both Zenkuda (tarcocimab tedromer) and KSI-501 in wet age-related macular degeneration (wet AMD), with both therapies successfully meeting primary endpoints. The strong data establishes statistical non-inferiority to Regeneron's blockbuster treatment Eylea, positioning Kodiak to accelerate a Biologics License Application (BLA) filing in the fourth quarter. Given the definitive clinical success and the removal of a massive binary risk, institutional interest is expected to remain highly active as analysts re-rate the pipeline and the market anticipates subsequent presentations and December trial readouts.

Flow Intent Analysis

The massive, disproportionate options premium concentrated heavily in bullish contracts following the morning's positive data release, indicating a major institutional re-rating of Kodiak's pipeline rather than reactive hedging.

One email a week. Catch up in five minutes.

The GammaRips weekly briefing — engine state, the latest Lab experiment, and what the pool's outcome data showed. No firehose, no FOMO.

Free weekly newsletter. No spam. Unsubscribe anytime.

Read the 2026-09-29 morning briefing for the full scan this KOD row came from: the shape of the pool that day, the themes in the flow, and every other name in it.

How We Read This Flow

Plain-English explainers on the methodology behind signals like this one.

View all →

One email a week. Catch up in five minutes.

The GammaRips weekly briefing — engine state, the latest Lab experiment, and what the pool's outcome data showed. No firehose, no FOMO.

Free weekly newsletter. No spam. Unsubscribe anytime.

    We Use Cookies

    We use cookies to enhance your experience, analyze site traffic, and for marketing purposes. By clicking "Accept," you agree to our use of cookies. Read our Privacy Policy.